Pediatric Puzzler: He won't walk and isn't talking much—what's the next step for a 2-year-old?

Article

You remain concerned that he has a serious problem. Might he have one of the more common diagnoses in a 2-year-old who refuses to walk?

Recent Videos
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Related Content
Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins | Image Credit: © 125154153 - stock.adobe.com.

Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins

Joshua Fitch, Senior Editor
June 18th 2025
Article

Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
FDA accepts NDA for epinephrine sublingual film to treat type 1 allergic reactions | Image credit: Contemporary Pediatrics

FDA accepts NDA for epinephrine sublingual film to treat type 1 allergic reactions

Joshua Fitch, Senior Editor
June 17th 2025
Article

The federal agency has assigned a target action date of January 31, 2026, for a decision.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
FDA will not meet original PDUFA data for sebetralstat to treat HAE | Image Credit: Contemporary Pediatrics

FDA will not meet original PDUFA date for sebetralstat to treat HAE

Joshua Fitch, Senior Editor
June 16th 2025
Article

Though the decision will not meet the June 17, 2025, target date, the federal agency anticipates a decision within approximately 4 weeks.

FDA approves new presentation of ustekinumab-stba biosimilar for plaque psoriasis, psoriatic arthritis | Image Credit: Contemporary Pediatrics

FDA approves new presentation of ustekinumab-stba biosimilar for plaque psoriasis, psoriatic arthritis

Joshua Fitch, Senior Editor
June 16th 2025
Article

The approval for ustekinumab-stba now offers all dosage forms to the reference product, ustekinumab, and is indicated for patients aged 6 to 17 years.

© 2025 MJH Life Sciences

All rights reserved.